A chimeric live attenuated vaccine against Japanese encephalitis.
Japanese encephalitis is a disease of the CNS, endemic in Asia and Oceania. The disease is refractory to drug treatments and whilst the rural economies remain heavily dependent on agriculture, conditions for propagation of the disease will persist. Thus, there is a need for effective vaccines. Although some currently exist, they have their shortcomings. ChimeriVax-JE (Acambis Inc.) is a chimeric, live attenuated vaccine which expresses protective Japanese encephalitis antigens and to date has proven to be safe, effective and well-tolerated in clinical trials. It therefore appears to be a cost-effective prophylactic vaccine against this debilitating disease.
Jones
Taff
T
ID Biomedical Corp. of Quebec, 7150 Frederick Banting, Montreal H4S 2A1, Quebec, Canada. tjones@idbiomedical.com
D003362:Cost-Benefit Analysis; D004664:Encephalitis Virus, Japanese / Q000235:genetics / Q000276:immunology; D004672:Encephalitis, Japanese / Q000191:economics / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D022321:Japanese Encephalitis Vaccines / Q000191:economics / Q000276:immunology*; D016032:Randomized Controlled Trials as Topic; D016865:Reassortant Viruses / Q000235:genetics / Q000276:immunology; D014613:Vaccines, Attenuated / Q000191:economics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology; D015005:Yellow fever virus / Q000235:genetics / Q000276:immunology
D022321:Japanese Encephalitis Vaccines; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic